Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.2K
Abnormal Proliferation02:23

Abnormal Proliferation

4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Conflating polycythemia vera with essential thrombocytosis.

Blood advances·2025
Same author

Sex specific definitions of anaemia reflect androgen production.

The Lancet. Haematology·2022
Same author

HMGA1 chromatin regulators induce transcriptional networks involved in GATA2 and proliferation during MPN progression.

Blood·2022
Same author

Advances in polycythemia vera and lessons for acute leukemia.

Best practice & research. Clinical haematology·2021
Same author

Are polycythemia vera, essential thrombocytosis, and primary myelofibrosis 1, 2, or 3 diseases?

Leukemia·2021
Same author

The Thrombopoietin Receptor, MPL, Is a Therapeutic Target of Opportunity in the MPN.

Frontiers in oncology·2021
Same journal

Evidence-Based Clinical Recommendations for the Appropriate Use of Diagnostic Tests in Pediatric Allergology: Focus on Asthma, Rhinoconjunctivitis, and Keratoconjunctivitis Vernal.

Journal of clinical medicine·2026
Same journal

Surgical and Transcatheter Approach of a Failed Mitral Valve Repair: A Comprehensive Review on Selecting the Most Suitable Approach.

Journal of clinical medicine·2026
Same journal

Hybrid Metaheuristic Feature Selection for Breast Cancer Detection in Digital Mammography: A Feasibility Study with Nested Validation, Benchmarking, and External Stress Testing.

Journal of clinical medicine·2026
Same journal

Identity Transformation and the Role of Accountability in Recovery from Problematic Pornography Use: A Phenomenological-Hermeneutical Study.

Journal of clinical medicine·2026
Same journal

Does Early Surgical Treatment in Degenerative Cervical Myelopathy Have a Favorable Clinical Outcome and Impact on Quality of Life?

Journal of clinical medicine·2026
Same journal

Shear Wave Elastography in Musculoskeletal Imaging: A Narrative Review.

Journal of clinical medicine·2026
See all related articles

Related Experiment Video

Updated: Jun 6, 2025

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

9.9K

Myeloproliferative Neoplasms: Challenging Dogma.

Jerry L Spivak1

  • 1Hematology Division, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.

Journal of Clinical Medicine
|November 27, 2024
PubMed
Summary
This summary is machine-generated.

Myeloproliferative neoplasms (MPNs) are rare blood cancers with shared mutations. This review examines how recent genomic discoveries can improve MPN diagnosis and management, resolving long-standing clinical disputes.

Keywords:
ARCHCHIPMPN driver mutationsacute leukemiablood volumediagnostic criteriahematopoietic stem cellshydroxyureamyelofibrosisnatural historyphlebotomy

More Related Videos

Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.0K
Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

11.5K

Related Experiment Videos

Last Updated: Jun 6, 2025

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

9.9K
Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.0K
Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

11.5K

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocytosis, and primary myelofibrosis, are clonal hematopoietic stem cell disorders.
  • These MPNs share driver mutations (JAK2, CALR, MPL) leading to similar features like abnormal blood cell production and potential leukemic transformation.
  • Despite well-defined natural histories, MPN management remains controversial, particularly regarding thrombosis prevention and the role of chemotherapy.

Purpose of the Study:

  • To review the conflicts between traditional phenotypic diagnostic criteria and newer genomic discoveries in MPNs.
  • To demonstrate how integrating genomic insights with phenotypic features can enhance MPN diagnosis and management.
  • To address ongoing debates in MPN therapy, such as thrombosis prevention and the long-term effects of treatments like hydroxyurea.

Main Methods:

  • Review of existing literature on myeloproliferative neoplasms, focusing on diagnostic criteria and therapeutic controversies.
  • Analysis of the impact of discovering somatic, gain-of-function driver mutations (JAK2, CALR, MPL) on MPN classification and treatment.
  • Examination of the interplay between phenotypic presentation and genetic underpinnings in MPN patient care.

Main Results:

  • The discovery of driver mutations has led to revised diagnostic criteria for MPNs, sometimes conflicting with established phenotypic approaches.
  • Genomic insights offer a complementary approach to understanding MPN pathogenesis and heterogeneity.
  • Ongoing disputes regarding thrombosis risk and treatment efficacy persist, highlighting the need for integrated diagnostic and management strategies.

Conclusions:

  • Genomic discoveries have significantly advanced the understanding of myeloproliferative neoplasms.
  • Integrating genetic findings with clinical phenotypes is crucial for refining MPN diagnosis and personalized management.
  • Further research is needed to fully resolve therapeutic controversies and optimize patient outcomes in MPNs.